Amgen News ServiceThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• Contents
• Discussions

Pages: 1  2  

Amgen to Present at Lazard Capital Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - November 16, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen to Present at 18th Annual Credit Suisse Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - November 12, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.  Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC. (Source: Amgen News Service)
Source: Amgen News Service - November 5, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Call for Applications: The Amgen Award for Science Teaching ExcellenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE).  This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates. (Source: Amgen News Service)
Source: Amgen News Service - November 4, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy EndpointsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovas...
Source: Amgen News Service - October 30, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008. (Source: Amgen News Service)
Source: Amgen News Service - October 21, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Oct 19, 2009 – Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis. The FDA issues Complete Response Letters to request additional information needed to complete the review of applications for product approval.  (Source: Amgen News Service)
Source: Amgen News Service - October 18, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Amgen Announces Webcast of 2009 Third Quarter Financial ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Oct. 15 – Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 21, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service)
Source: Amgen News Service - October 14, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept 24, 2009 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘203’ trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard ratio 0.80; p=0.02)) in patients with KRAS wild-type mCRC (primary endpoint). The results were presented at the 2009 ECCO 15 - ESMO 34 Euro...
Source: Amgen News Service - September 23, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News, Pipeline News Source Type: organizations

Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘181’ trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA). (Source: Amgen News Service)
Source: Amgen News Service - September 21, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News, Pipeline News Source Type: organizations

Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 2LBA). (Source: Amgen News Service)
Source: Amgen News Service - September 21, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone MetastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 21 – Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA). (Source: Amgen News Service)
Source: Amgen News Service - September 20, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Amgen to Present at the UBS Global Life Sciences ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 17 – Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Monday, Sept. 21, 2009, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - September 16, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science ResearchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Symposium Offers Unique Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects (Source: Amgen News Service)
Source: Amgen News Service - September 15, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 CongressEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented: Amgen announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.  (Source: Amgen News Service)
Source: Amgen News Service - September 15, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

Amgen to Present at the Bank of America Merrill Lynch Global Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 14 – Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 17, 2009, in London, beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - September 13, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal OsteoporosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DENVER – Sept. 13 – Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR). (Source: Amgen News Service)
Source: Amgen News Service - September 12, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen to Present at the Morgan Stanley Global Healthcare Unplugged ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 11 – Amgen (Nasdaq: AMGN) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009, at the Grand Hyatt hotel in New York City, beginning at 12:00 p.m. Eastern Time. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - September 10, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 10 – Amgen (Nasdaq: AMGN) today announced that new data will be presented on the burden of osteoporosis, current osteoporosis treatment challenges and Prolia(TM) (denosumab) at the 2009 American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from Sept. 11-15, 2009. Prolia currently is being evaluated by regulatory bodies in the United States (U.S.), the European Union, Switzerland, Australia and Canada as a potential therapy for postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation for prostate and breast cancer. (Source: Amgen News Service)
Source: Amgen News Service - September 9, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For HopeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LEWISTON, Maine and THOUSAND OAKS, Calif. – Sept. 9 – Amgen has signed on as the presenting sponsor of The Dempsey Challenge: A Journey for Hope, a cycling and 5K fundraising event scheduled for October 4 in Lewiston, Maine. The event supports The Patrick Dempsey Center for Cancer Hope & Healing at Central Maine Medical Center. (Source: Amgen News Service)
Source: Amgen News Service - September 8, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Philanthropy, Press Releases Source Type: organizations

Amgen to Present at the Thomas Weisel Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 8 – Amgen (Nasdaq: AMGN) will participate in the Thomas Weisel Healthcare Conference on Friday, Sept. 11, 2009, at the Four Seasons in Boston, Mass. beginning at 8:35 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - September 7, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen to Present at the Baird Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Sept. 4 – Amgen (Nasdaq: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 10, 2009, at the Four Seasons in New York City, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development, for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - September 3, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of PsoriasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Eight Contest Winners Model Custom-Designed Outfits to Show that Moderate to Severe Plaque Psoriasis Does Not Impact Their Personal Style NEW YORK – Sept. 2 – Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn’s Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City. The fashion show recognizes people with moderate to severe plaque psoriasis who have not allowed the condition to inhibit their personal style. Winners of the Addressing Psoriasis(...
Source: Amgen News Service - September 1, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif.—Aug. 25—Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type 2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp(R) (darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. (Source: Amgen News Service)
Source: Amgen News Service - August 24, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show Progression-Free Survival Advantage in KRAS Wild-Type Population THOUSAND OAKS, Calif. – Aug. 17 – Amgen (Nasdaq: AMGN) today announced positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival. (Source: Amgen News Service)
Source: Amgen News Service - August 16, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health DrugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
 Committee to Review Denosumab in Women with Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation Therapy for Either Prostate or Breast Cancer THOUSAND OAKS, Calif. – Aug 13, 2009 – Amgen Inc. (Nasdaq: AMGN) today will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer patients undergoing hormone ablation at a meeting with the U.S. Food and Drug Administration’s (FDA) Advisory Committee for Reproductive Health Drug...
Source: Amgen News Service - August 12, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – Aug 13, 2009 – Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today’s meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer or breast cancer. (Source: Amgen News Service)
Source: Amgen News Service - August 12, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone LossEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Twice-Yearly Administration of Denosumab Resulted in 68 Percent Reduction in Risk for a Vertebral Fracture and 40 Percent Reduction in Risk for a Hip Fracture in Women with Postmenopausal Osteoporosis Denosumab Administered Twice-Yearly Reduced the Incidence of New Vertebral Fractures by 62 Percent in Men with Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy     THOUSAND OAKS, Calif. – Aug. 11 /PRNewswire-FirstCall – Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of de...
Source: Amgen News Service - August 10, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type KRAS Population Phase 3 Results Reinforce Importance of KRAS Testing THOUSAND OAKS, Calif. – Aug. 6 – Amgen (Nasdaq: AMGN) today announced that Vectibix (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). (Source: Amgen News Service)
Source: Amgen News Service - August 5, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events THOUSAND OAKS, Calif. – Aug. 3 – Amgen (Nasdaq: AMGN) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. (Source: Amgen News Service)
Source: Amgen News Service - August 2, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Amgen Statement on the House Energy & Commerce Committee’s Approval of an Amendment to Create a Biosimilars PathwayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The following statement was issued today by Amgen on the passage of the Eshoo-Inslee-Barton amendment to the House Energy & Commerce Committee’s health care reform legislation. The strong bipartisan support in the Energy and Commerce Committee for a fair and balanced pathway for the approval of biosimilars is a win for patients. The amendment introduced by Representatives Eshoo, Inslee and Barton and overwhelmingly approved by the Committee strikes a necessary balance in allowing access to safe and effective biosimilar medicines for patients, and providing fair incentives for the discovery of new medicines for se...
Source: Amgen News Service - July 30, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Company Statements Source Type: organizations

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 Billion Second Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.25 2009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to $4.80-$4.95 THOUSAND OAKS, Calif. –July 27 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.29 for the second quarter of 2009, an increase of 13 percent compared to$1.14 for the second quarter of 2008. Adjusted net inco...
Source: Amgen News Service - July 26, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amgen to Retain Full Rights for Denosumab in the United States and Canada and for Oncology Indications in Europe GlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging Markets THOUSAND OAKS, Calif. and LONDON – July 27 – Amgen (Nasdaq: AMGN) andGlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) inEurope, Australia, New Zealand and Mexico once the produ...
Source: Amgen News Service - July 26, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Amgen Scholars Discover Their Potential During Summer Science Research Program and National SymposiumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – July 20, 2009 – From July 18-20, more than 260 of the country’s brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers. (Source: Amgen News Service)
Source: Amgen News Service - July 19, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Philanthropy, Press Releases Source Type: organizations

Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr Antibody Monotherapy in Metastatic Colorectal Cancer Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in Combination Therapy Expected In Third Quarter 2009  THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab). This decision follows the FDA’s December 2008 Oncologics D...
Source: Amgen News Service - July 16, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

Amgen Appoints Rebecca M. Henderson to the Company's Board of DirectorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – July 9 – Amgen (Nasdaq: AMGN) announced today that its Board of Directors has appointed Rebecca M. Henderson, Ph.D., to the Company’s Board. Dr. Henderson, 48, has recently joined the faculty at the Harvard Business School, having been the Eastman Kodak LFM Professor of Management at the Massachusetts Institute of Technology (MIT) Sloan School since 1999. She specializes in technology strategy and the broader strategic problems faced by firms in high technology industries. From 1995 to 1999, Dr. Henderson was a tenured associate professor at the MIT Sloan School. She has been a directo...
Source: Amgen News Service - July 8, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone MetastaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Denosumab Significantly Delayed the Time to the First Skeletal Related Event and Significantly Reduced First and Subsequent Skeletal Related Events Compared to Zometa First of Three Pivotal Oncology Trials Comparing Denosumab to Zometa in the Advanced Cancer Setting Meets Primary and Secondary Endpoints THOUSAND OAKS, Calif. – July 7 – Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated supe...
Source: Amgen News Service - July 6, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Pipeline News Source Type: organizations

Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim GunnEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK – July 6 – Amgen and Wyeth today announced the eight winners of the Addressing Psoriasis(TM) contest, which recognizes people with moderate to severe plaque psoriasis who have tried not to allow the condition to inhibit their personal style. The winners will help raise public awareness of the condition by walking the runway in the Addressing Psoriasis(TM) Fashion Show hosted by television host and fashion consultant, Tim Gunn ("Project Runway," and "Tim Gunn’s Guide to Style"), on Sept. 2, 2009. (Source: Amgen News Service)
Source: Amgen News Service - July 5, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching ExcellenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – June 17, 2009 – Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year’s recipients of the Amgen Award for Science Teaching Excellence. The award recognizes teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the future generation of scientists. (Source: Amgen News Service)
Source: Amgen News Service - June 16, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Philanthropy, Press Releases Source Type: organizations

Statement in Response to FTC Report on BiosimilarsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif.–June 10, 2009–As a biotechnology pioneer committed to developing first-in-class medicines that treat serious illnesses and unmet health needs, Amgen believes that an abbreviated biosimilar approval pathway must not discourage the development of groundbreaking new treatments for serious diseases.  (Source: Amgen News Service)
Source: Amgen News Service - June 10, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Company Statements Source Type: organizations

New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITPEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BERLIN – June 7 – Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were present...
Source: Amgen News Service - June 8, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic ResistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population THOUSAND OAKS, Calif. – May 27, 2009 – Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as well as emerging antibiotic resistance. Nearly all oncologists surveyed (92 percent) believe it is important for cancer patients to preve...
Source: Amgen News Service - May 27, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/—Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics’ cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure. (Source: Amgen News Service)
Source: Amgen News Service - May 26, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Highlights Data to Be Presented at ASCOEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif. – May 15 – Amgen (Nasdaq: AMGN) today announced it will present new data from the Company’s oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. fromMay 29 to June 2, 2009. Data will be presented from several programs, including Vectibix(R)...
Source: Amgen News Service - May 15, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News, Pipeline News Source Type: organizations

Amgen to Present at the Deutsche Bank 34th Annual Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – May 13 – Amgen (Nasdaq: AMGN) will present at theDeutsche Bank 34th Annual Healthcare Conference on Monday, May 18, 2009 at the InterContinental,Boston, Mass., beginning at 9:20 a.m. Eastern Time. Chairman and Chief Executive Officer  Kevin Sharer will present. Live audio of the presentation will be available over the Internet and can be accessed fromAmgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service)
Source: Amgen News Service - May 13, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New CampaignEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – April 30 – Amgen and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today announced that they will partner alongside celebrity make-up artist and cancer survivor Jan Ping to support a new educational campaign, Coping with Cancer From the Outside In. The initiative is aimed at educating oncology nurses about the skin-related side effects associated with epidermal growth factor receptor (EGFR) inhibitors that are used to treat metastatic colorectal, lung, pancreatic, and head and neck cancers. (Source: Amgen News Service)
Source: Amgen News Service - April 30, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen and Wyeth announce ENBREL Support™ ProgramEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amgen and Wyeth remain committed to helping to provide clinically appropriate patients access to Enbrel® (etanercept), despite tough economic times. Once physicians and their patients have determined that ENBREL is the right treatment choice, patients may benefit from the ENBREL Support™ program, which offers financial support to eligible patients in several ways, depending on their specific situation. (Source: Amgen News Service)
Source: Amgen News Service - April 24, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Product News Source Type: organizations

Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion  First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98 2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to $14.4 to $14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range Maintained at $4.55 to $4.75   THOUSAND OAKS, Calif. – April 23 /– Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first quarter of 2009, a decrease of 4 percent compared to $1.12for the first quarter of 2008. Adjusted net income decre...
Source: Amgen News Service - April 23, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Announces Webcast of 2009 First Quarter Financial ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif. – April 20 – Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Thursday, April 23, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service)
Source: Amgen News Service - April 20, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

Amgen Introduces New Amgentrials.comEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amgen today launched the new Amgentrials.com website (http://www.amgentrials.com), an important resource for patients, physicians, and others who seek information about the company’s clinical trials. (Source: Amgen News Service)
Source: Amgen News Service - April 17, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Company Statements Source Type: organizations